SCHEMBL3765824

SCHEMBL3765824

CCCCOC(=O)Nc1ccccc1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 12/20 0.69
NPC1 O15118 11/20 0.69
SMN1; SMN2 Q16637 10/20 0.69
RECQL P46063 1/20 0.69
HPGD P15428 6/20 0.68
LMNA P02545 3/20 0.68
MAPT P10636 3/20 0.68
ALDH1A1 P00352 2/20 0.68
CASP1 P29466 1/20 0.68
KDM4E B2RXH2 1/20 0.68
MAPK1 P28482 1/20 0.68
MCL1 Q07820 1/20 0.68
L3MBTL1 Q9Y468 1/20 0.68
CYP1A2 P05177 3/20 0.63
CYP2C19 P33261 3/20 0.63
CYP2C9 P11712 2/20 0.63
TP53 P04637 2/20 0.61
TSHR P16473 1/20 0.61
KMT2A Q03164 3/20 0.59
MEN1 O00255 2/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8600999 0.95 RAB9A (0.67) RAB9ANPC1SMN1; SMN2RECQLHPGD
SCHEMBL1837292 0.93 RAB9A (0.65) RAB9ANPC1SMN1; SMN2RECQLHPGD
SCHEMBL7995030 0.93 RAB9A (0.65) RAB9ANPC1SMN1; SMN2RECQLHPGD
SCHEMBL6767997 0.93 RAB9A (0.65) RAB9ANPC1SMN1; SMN2RECQLHPGD
SCHEMBL8076542 0.93 RAB9A (0.65) RAB9ANPC1SMN1; SMN2RECQLHPGD
SCHEMBL7653371 0.93 RAB9A (0.65) RAB9ANPC1SMN1; SMN2RECQLHPGD
SCHEMBL1834100 0.93 RAB9A (0.65) RAB9ANPC1SMN1; SMN2RECQLHPGD
SCHEMBL8600460 0.93 RAB9A (0.65) RAB9ANPC1SMN1; SMN2RECQLHPGD
SCHEMBL10599124 0.93 RAB9A (0.65) RAB9ANPC1SMN1; SMN2RECQLHPGD
SCHEMBL7564852 0.91 RAB9A (0.79) RAB9ANPC1SMN1; SMN2RECQLHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101356173-A Novel pyridopyrazines and their use as modulators of kinases AETERNA ZENTARIS GMBH (DE) 2009-01-28 CN claimed
US-7405319-B2 Process for the preparation of carbamates COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2008-07-29 US claimed
US-20070270605-A1 Process for the preparation of carbamates COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2007-11-22 US claimed
CN-1382119-A Substituted alpha-hydroxy acid caspase inhibitors and uses thereof CYTOVIA INC (US) 2002-11-27 CN claimed
US-5091556-A Catalytic reacting carbonate with amine ENICHEM SYNTHESIS, S.P.A. (IT) 1992-02-25 US claimed
US-5079383-A With A Methylating Agent Using A Zinc Halide Catalyst MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) 1992-01-07 US claimed
US-12623999-B2 Carbamate production method, carbamate ester production method, and urea derivative production method NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 2026-05-12 US disclosed
EP-4612156-A1 ANTI-VIRAL COMPOUNDS Aligos Therapeutics, Inc. (US) 2025-09-10 EP disclosed
US-20240425448-A1 METHOD FOR PRODUCING ISOCYANATE COMPOUND, METHOD FOR PRODUCING CARBAMATE COMPOUND, METHOD FOR RECOVERING AMINE COMPOUND, AND ISOCYANATE COMPOSITION ASAHI KASEI KABUSHIKI KAISHA (JP) 2024-12-26 US disclosed
EP-4431490-A1 METHOD FOR PRODUCING ISOCYANATE COMPOUNDS, METHOD FOR PRODUCING CARBAMATE COMPOUNDS, METHOD FOR RECOVERING AMINE COMPOUNDS, AND ISOCYANATE COMPOSITION Asahi Kasei Kabushiki Kaisha (JP) 2024-09-18 EP disclosed
CN-118215651-A Method for producing isocyanate compound, method for producing urethane compound, method for recovering amine compound, and isocyanate composition 旭化成株式会社 2024-06-18 CN disclosed
WO-2024097296-A1 ANTI-VIRAL COMPOUNDS ALIGOS THERAPEUTICS, INC. (US) 2024-05-10 WO disclosed
US-20230212110-A1 CARBAMATE PRODUCTION METHOD, CARBAMATE ESTER PRODUCTION METHOD, AND UREA DERIVATIVE PRODUCTION METHOD NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 2023-07-06 US disclosed
US-4260781-A Process for the manufacture of carbamates HALCON RESEARCH AND DEVELOPMENT CORP. (US) 1981-04-07 US disclosed
US-4258201-A CATALYTIC CARBONYLATION OF PRIMARY OR SECONDARY AMINES WITH CARBON MONOXIDE AND ALCOHOLS HALCON RESEARCH AND DEVELOPMENT CORP. (US) 1981-03-24 US disclosed
US-4243815-A Preparation of methylene-bis(4-phenylcarbamic acid esters) BASF AKTIENGESELLSCHAFT (DE) 1981-01-06 US disclosed
US-4242520-A ONE-STEP CARBONYLATION OF AMINES IN THE PRESENCE OF A DISULFIDE HALCON RESEARCH & DEVELOPMENT CORPORATION (US) 1980-12-30 US disclosed
EP-0014103-A2 Improved process for the manufacture of carbamates THE HALCON SD GROUP, INC. (US) 1980-08-06 EP disclosed
US-4081472-A CATALYTIC, FROM A CARBAMATE MITSUI TOATSU CHEMICALS INC. (JA) 1978-03-28 US disclosed
US-3938986-A ISOPROPYL N-PHENYLCARBAMATE OR ISOPROPYL N-(3-CHLOROPHENYL)CARBAMATE AND 4-CHLOROPHENYL N-METHYLCARBAMATE PPG INDUSTRIES, INC. (US) 1976-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12623999-B2 Carbamate production method, carbamate ester production method, and urea derivative production method CPS1, CA2, CHRM2 RAB9A 1485/4885NPC1 835/4885SMN1; SMN2 3022/4885
US-20230212110-A1 CARBAMATE PRODUCTION METHOD, CARBAMATE ESTER PRODUCTION METHOD, AND UREA DERIVATIVE PRODUCTION METHOD CPS1, ATM, OAT RAB9A 2285/4885NPC1 617/4885SMN1; SMN2 4152/4885
US-20240425448-A1 METHOD FOR PRODUCING ISOCYANATE COMPOUND, METHOD FOR PRODUCING CARBAMATE COMPOUND, METHOD FOR RECOVERING AMINE COMPOUND, AND ISOCYANATE COMPOSITION IDH3A, CA7, C9 RAB9A 3205/4885NPC1 666/4885SMN1; SMN2 2354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.